Truist Financial Corporation logo TFC - Truist Financial Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 27
HOLD 24
SELL 3
STRONG
SELL
0
| PRICE TARGET: $54.25 DETAILS
HIGH: $62.00
LOW: $45.00
MEDIAN: $55.00
CONSENSUS: $54.25
UPSIDE: 19.02%

Stock News

Truist Q3 Earnings Preview: When Rates Go Boom

Truist Q3 Earnings Preview: When Rates Go Boom

Truist Financial Corporation enters Q3 2026 earnings with new CEO Michael Lyons, whose strategic direction will be a key focus. Recent $5.5B auto loan sale and exit from less profitable businesses signal ongoing portfolio optimization, with near-term NIM pressure but improved credit quality. Interest rate sensitivity remains contained; TFC's balance sheet is well positioned for gradual rate increases, though macro risks persist.

Oct 05, 2026 05:15 AM • seekingalpha.com
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included cUHDRS & TFC four-year data. cUHDRS at year 4 showed 44% slowing, with a non-significant p=0.144. Per QURE, this may have been due to missing data & “survivor bias” in the external control arm. TFC (total functional capacity) data consistently show >60% slowing of disease progression with statistically significant p-values, albeit nominal ones. TFC is the FDA-aligned confirmatory p3 trial's primary endpoint.

Sep 30, 2026 09:17 AM • seekingalpha.com
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~

Sep 29, 2026 03:12 AM • globenewswire.com
First Capital (NASDAQ:FCAP) & Truist Financial (NYSE:TFC) Head-To-Head Review

First Capital (NASDAQ:FCAP) & Truist Financial (NYSE:TFC) Head-To-Head Review

Truist Financial (NYSE: TFC - Get Free Report) and First Capital (NASDAQ: FCAP - Get Free Report) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Earnings and Valuation This table compares Truist Financial

Sep 29, 2026 02:15 AM • defenseworld.net
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs

Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs

Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October 2024. It's still true more than ever as 10-yr bonds yield >5%. Interviewed by Barron's, Steven Wieting, strategist at Citi Wealth, noted growing dividends benefit shareholders and identify companies with strong balance sheets. “Nobody can fake a dividend,” he said.

Sep 26, 2026 06:13 AM • seekingalpha.com

Price Targets